
Sign up to save your podcasts
Or


Guest: Mitchell R. Humphreys, M.D. (@MayoMitch)
Host: Darryl S. Chutka, M.D. (@ChutkaMD)
Prostate cancer is a very common malignancy in men, second only to skin cancer. Despite the fact that it’s one of the more treatable malignancies, it remains the 2nd leading cause of cancer death in men. When diagnosed early, it has an excellent prognosis. The 5-year survival rate approaches 100% in those with local or regional disease. Although screening for prostate cancer is available, the use of screening tests has been controversial and recommendations regarding its use, confusing. Listen in to get a urologist’s perspective.
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
By Mayo Clinic4.4
276276 ratings
Guest: Mitchell R. Humphreys, M.D. (@MayoMitch)
Host: Darryl S. Chutka, M.D. (@ChutkaMD)
Prostate cancer is a very common malignancy in men, second only to skin cancer. Despite the fact that it’s one of the more treatable malignancies, it remains the 2nd leading cause of cancer death in men. When diagnosed early, it has an excellent prognosis. The 5-year survival rate approaches 100% in those with local or regional disease. Although screening for prostate cancer is available, the use of screening tests has been controversial and recommendations regarding its use, confusing. Listen in to get a urologist’s perspective.
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

319 Listeners

705 Listeners

506 Listeners

298 Listeners

260 Listeners

895 Listeners

3,360 Listeners

1,152 Listeners

517 Listeners

373 Listeners

12 Listeners

18 Listeners

15 Listeners

9 Listeners

257 Listeners

439 Listeners

313 Listeners

45 Listeners

14 Listeners

327 Listeners

268 Listeners